TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00927901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol xinafoate 400 μg
Description: Indacaterol xinafoate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol xinafoate 400 μg
Description: Indacaterol xinafoate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to indacaterol
Description: Placebo to indacaterol was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to indacaterol
Description: Placebo to indacaterol was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to indacaterol
Description: Placebo to indacaterol was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to indacaterol
Description: Placebo to indacaterol was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler.
Study: NCT01306006

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Providing measles vaccine for all children 9-35 months who have not yet received a routine measles vaccine
Description: Normal measles vaccines licensed for distribution through the national EPI program
Study: NCT03927183

Intervention type: OTHER
Group type: OTHER
Intervention: person-centred practice
Description: The structure and content of the intervention is constructed on principles for person-centredness. Each patients in the intervention are allocated a hospital-initiated nurse care manager during one year after surgery. Self-management support is primarily conducted between the patient and the nurse care manager. The primary goal of the support is to facilitate patients own resources in managing illness and health education on e.g. physical activity and diet. The support also comprises patient-held documentation and health plan. Other components of the intervention comprise accessibility and continuity which is secured by a structured clinical care pathway with planned care and defined care contacts. The patient has continuous access to the nurse care manager by telephone and face-to-face contact according to a structured follow-up plan. An interdisciplinary team as well as a patient education program constitutes distinct parts of the support during the year after surgery.
Study: NCT02802358

Intervention type: PROCEDURE
Intervention: Surgery or non-invasive procedure (reduction of the fracture, immobilization, stabilization)

Intervention type: PROCEDURE
Intervention: Surgery or non-invasive procedure (reduction of the fracture, immobilization, stabilization)
Study: NCT00546247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epofolate
Description: Intravenous solution, intravenous, initially 3 patients will be treated and if there is a DLT then additional 3 patients will be treated in that dose level. 3-5 minute IV bolus on Days 1, 4, 8 and 11 of a 21-day cycle, until the disease progresses
Study: NCT01320878

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iloprost nebuliser solution
Description: iloprost 30 ng/kg/min inhalation for 10 minutes,q4h in day time and q6h at night for 2 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iloprost nebuliser solution
Description: iloprost 50 ng/kg/min inhalation for 10 minutes, q4h in day time and q6h at night for 2 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: distilled water
Description: distilled water 2 ml per session
Study: NCT00904709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Description: After The starting dose of tranexamic acid will be 500 mg twice daily beginning the first day of menstrual flow for a total of 6 days per menstrual cycle. If after 2 days there is still menorrhagia without significant side effects the will be increased. The women will be assessed again at day 4 and 9 and dose escalation will continue until they have reached the optimal dose.The dose of tranexamic acid will be increased as follows: 1000 mg twice daily, 1000 mg three times daily, 1500 mg/1000 mg/1000 mg, 1000 mg four times daily, 1500 mg three times daily, and 1500 mg four times daily (maximum dose).Each patient will be followed for a minimum of one menstrual cycle and a maximum of 3 cycles.
Study: NCT01258647

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: caterpillar cereal
Description: A 30 gram portion of a cereal containing one part dried, ground caterpillar, one part corn flour and small quantities of sugar and palm oil will be evaluated by the mothers and then fed daily for seven days to infants.
Study: NCT03722511

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Amino Acid Based Medical Food/Drink
Description: Study Compound Enterade® is a medical food drink/beverage composed of a proprietary blend of electrolytes and amino acids.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Amino Acid Based Medical Food/Drink
Description: Study Compound Enterade® is a medical food drink/beverage composed of a proprietary blend of electrolytes and amino acids.
Study: NCT03521752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific Exercise Program
Description: 4 weeks of exercise classes, 2 to 3 times a week for a total of 10 sessions. Classes last approximately 40 minutes. The sessions included balance training, motor strength, endurance and flexibility. The training sessions were divided into warm-up, main activity and finally relaxation.
Study: NCT03152487

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Celiac Plexus Neurolysis
Description: This intervention involves accessing the Celiac Plexus Nerve via endoscopic guided ultrasound and then injecting the nerve bundle with bupivacaine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Ablation
Description: Radiofrequency ablation is performed via the probe for 90 seconds, followed by a 90 second rest. This is repeated until the entire ganglion becomes hyperechoic on EUS.
Study: NCT02437643

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss
Description: Participants will be prescribed hypo-caloric diet prescription.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Weight Loss
Description: Participants will be prescribed hypo-caloric diet prescription.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dairy Protein
Description: Participants will be provided dairy products: WL-LoEx will be provided 1 dairy serving per day and Pro-WL-LoEx will be provided 8 dairy servings per day.
Study: NCT01869140

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spinal manual therapy
Description: spinal manipulation either manual or instrumental (activator)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spinal manual therapy
Description: spinal manipulation either manual or instrumental (activator)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: spinal manual therapy
Description: spinal manipulation either manual or instrumental (activator)
Study: NCT03518242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo biospecimen collection
Study: NCT04751240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SIT and resistance training
Description: Participants complete 30 sessions of sprints and resistance training. Outcomes are assessed acutely and at 6 months.
Study: NCT03226301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib + Venetoclax 15 cycles
Description: Cycle 1 + 2: 420 mg ibrutinib, day 1-28 \| Cycle 3: 420 mg ibrutinib, day 1-28 \| 20 mg venetoclax, day 1-7 \| 50 mg venetoclax, day 8-14 \| 100 mg venetoclax, day 15-21 \| 200 mg venetoclax, day 22-28 \| Cycle 4-15: 420 mg ibrutinib, day 1-28 + 400mg venetoclax, day 1-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib + Venetoclax 15 cycles
Description: Cycle 1 + 2: 420 mg ibrutinib, day 1-28 \| Cycle 3: 420 mg ibrutinib, day 1-28 \| 20 mg venetoclax, day 1-7 \| 50 mg venetoclax, day 8-14 \| 100 mg venetoclax, day 15-21 \| 200 mg venetoclax, day 22-28 \| Cycle 4-15: 420 mg ibrutinib, day 1-28 + 400mg venetoclax, day 1-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib + Venetoclax 15 cycles
Description: Cycle 1 + 2: 420 mg ibrutinib, day 1-28 \| Cycle 3: 420 mg ibrutinib, day 1-28 \| 20 mg venetoclax, day 1-7 \| 50 mg venetoclax, day 8-14 \| 100 mg venetoclax, day 15-21 \| 200 mg venetoclax, day 22-28 \| Cycle 4-15: 420 mg ibrutinib, day 1-28 + 400mg venetoclax, day 1-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib until progression/relapse
Description: 420mg ibrutinib daily until progression/relapse

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib until progression/relapse
Description: 420mg ibrutinib daily until progression/relapse

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Possible reinitiation treatment: Ibrutinib + Venetoclax 12 cycles
Description: Cycle 1: 420 mg ibrutinib \| 20 mg venetoclax, day 1-7 \| 50 mg venetoclax, day 8-14 \| 100 mg venetoclax, day 15-21 \| 200 mg venetoclax, day 22-28 \| cycles 2-12: 420 mg ibrutinib, day 1-28 + 400 mg venetoclax, day 1-28
Study: NCT01962311

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lumbar puncture
Description: lumbar puncture at enrollment in study
Study: NCT00169845

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha-Tocopherol and Beta-Carotene
Description: Provided by Roche Vitamins Inc.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Provided by Roche Vitamins Inc
Study: NCT00739076

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Using Virtual Reality for pain control

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Using Virtual Reality for pain control

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Using Virtual Reality for pain control
Study: NCT02311088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02037776

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rikkunshito
Description: - Oral administration of rikkunshito (2.5 g t.i.d) before meals for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rikkunshito placebo
Description: - Oral administration of rikkunshito placebo (2.5 g t.i.d) before meals for 8 weeks
Study: NCT02881047

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 Laser
Description: Perform ablative fractional resurfacing using a 10,600nm carbon dioxide (CO2) laser targeted to thickened, sclerotic plaques causing range of motion limitation and contracture across joints.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Patients will undergo ultrasound of the planned treatment site to measure skin thickness and blood flow via Doppler ultrasound.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Skin Biopsy
Description: standard 4mm punch biopsy of the skin at the planned treatment site for histologic assessment of skin thickness and sclerosis.
Study: NCT02895321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cavex Bite&White ExSense
Description: a water-based mint aroma gel containing hydroxyapatite and potassium nitrate.
Study: NCT02437643

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dairy Protein
Description: Participants will be provided dairy products: WL-LoEx will be provided 1 dairy serving per day and Pro-WL-LoEx will be provided 8 dairy servings per day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity exercise
Description: Participants in both groups will participate in chair exercises 3 times a week.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Low intensity exercise
Description: Participants in both groups will participate in chair exercises 3 times a week.
Study: NCT00419159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (RAD001)
Description: Everolimus was supplied in 5 mg tablets in blister packs.
Study: NCT02895321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colgate, Protection Caries
Description: a fluorine-based toothpaste gels

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo gel
Description: a glycerin and water gel
Study: NCT04131764

Intervention type: DIAGNOSTIC_TEST
Intervention: Reflex (Brightlamp Inc., Purdue University)
Description: The Reflex pupillometer is a mobile based application that provides a quantitative way to monitor pupillary activity and responsiveness. It uses the mobile phone as a source of light and records pupillary response, as well as analyzes and compiles the data. It produces quantitative measures such as latency, minimum and maximum pupil diameter, maximum and average constriction velocity, dilation velocity, and 75% recovery time.

Intervention type: DIAGNOSTIC_TEST
Intervention: Reflex (Brightlamp Inc., Purdue University)
Description: The Reflex pupillometer is a mobile based application that provides a quantitative way to monitor pupillary activity and responsiveness. It uses the mobile phone as a source of light and records pupillary response, as well as analyzes and compiles the data. It produces quantitative measures such as latency, minimum and maximum pupil diameter, maximum and average constriction velocity, dilation velocity, and 75% recovery time.
Study: NCT04131764

Intervention type: DIAGNOSTIC_TEST
Intervention: Reflex (Brightlamp Inc., Purdue University)
Description: The Reflex pupillometer is a mobile based application that provides a quantitative way to monitor pupillary activity and responsiveness. It uses the mobile phone as a source of light and records pupillary response, as well as analyzes and compiles the data. It produces quantitative measures such as latency, minimum and maximum pupil diameter, maximum and average constriction velocity, dilation velocity, and 75% recovery time.
Study: NCT01214421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Tablets of 15 or 30 mg
Study: NCT00332969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Study: NCT02744339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat
Description: Adempas up-titrated to max. 1.5mg TID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sham-titrated TID
Study: NCT02574962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H.P. Acthar® Gel
Study: NCT02508597

Intervention type: OTHER
Group type: OTHER
Intervention: Physicians receiving smoking cessation training
Description: On the training day, the investigators will explain at the beginning of the workshop the purpose of the training, and the details of the brief smoking cessation intervention to all physicians who attend the training workshop.
Study: NCT03545412

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microfocused ultrasound with visualization
Description: Each subject to receive a minimum of 800 treatment lines, on two planes of treatment using the 4-4.5mm and 7-3.0mm transducer depths
Study: NCT03051893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chronocort
Description: Modified formulation of hydrocortisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chronocort
Description: Modified formulation of hydrocortisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chronocort
Description: Modified formulation of hydrocortisone
Study: NCT02772562

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-V/F
Description: 0.5 ml containing at least 2 x 108 Infectious Units (Inf.U) PROSTVAC-V given on day 1.~0.5 ml containing at least 1 x 109 Inf.U PROSTVAC-F given on days 15, 28, 57, 85, 113, 141.
Study: NCT03783689

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SPRINT Peripheral Nerve Stimulation (PNS) System
Description: The SPRINT System delivers mild electrical stimulation to nerves in the residual limb. The SPRINT System includes two small wires (called Leads) that are placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SPRINT Peripheral Nerve Stimulation (PNS) System
Description: The SPRINT System delivers mild electrical stimulation to nerves in the residual limb. The SPRINT System includes two small wires (called Leads) that are placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator).
Study: NCT03843398

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colorectal cancer resection via minilaparotomy
Description: According to the cancer location, a 7 cm incision is made in specific area of the patient's abdomen. The whole procedure of operation will be finished within this incision. If the incision must be lengthen due to the surgical demand, the failure of the minilaparotomy is determined.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic colorectal cancer resection
Description: This is one of the routine procedures used for colorectal cancer resection.
Study: NCT01495676

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Radiation + cisplatin
Description: RT will encompass bilateral internal and external iliac lymph nodes at a dose of 45 Gy and the bladder up to 63 Gy. Fractionation will be 1.8 Gy per fraction.~Cisplatin: 20 mg/m2/day through continuous iv perfusion for 4 consecutive days, from D2 to D5 and from D23 to D26 for the first part of the treatment, then from D2 to D5 if an additional treatment is decided.~A cystoscopy with a transurethral resection will be performed 3 weeks after the last day of the first part of radio-chemotherapy.~* In the absence of tumor cells, the 2nd part will start on the 4th week or at latest on the 5th week after the last day of the 1st part of radio-chemotherapy.~* In case of a microscopic tumor residue or of a local tumor progression, operability will be re-evaluated in view of a radical cystectomy and the patient will exit the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiation + cisplatin + gemcitabine
Description: Radiotherapy will encompass bilateral internal and external iliac lymph nodes at a dose of 45 Gy and the bladder up to 63 Gy. Fractionation will be 1.8 Gy per fraction.~Cisplatin: 20 mg/m2/day through continuous iv perfusion for 4 consecutive days, from D2 to D5 and from D23 to D26 for the first part of the treatment, then from D2 to D5 for the second part of the treatment if an additional treatment is decided.~Gemcitabine: iv injection for 30 minutes, twice a week at a dose of 25 mg/m2 on days 2, 5, 9, 12, 16, 19, 23, 26, 30, and 33 for the 1st part of treatment, then on days 2, 5, 9, and 12 for the 2nd part of treatment if an additional treatment is decided (cystoscopy with a transurethral resection). RT will be delivered between 2 and 6 hours after completion of the gemcitabine injection.
Study: NCT03941899

Intervention type: OTHER
Group type: OTHER
Intervention: Levobupivacaine in QLB II
Description: Quadratus Lomborum Block II type will be performed by injecting levobupivacaine 0.375% 20 ml between latissimus dorsi and quadratus lomborum muscle.
Study: NCT01779453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-1002
Description: Week 1-2, 60 mg/day; Week 3-4, 120 mg/day; Week 5-6, 180 mg/day; Week 7-8, 240 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 10mg once daily for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 10mg once daily for 8 weeks
Study: NCT02670122

Intervention type: DEVICE
Intervention: DEB-TACE
Description: Selective and ultraselective transcatheter intraarterial administration up to 3ml of well calibrated 100µ drug eluting microspheres with up to 150 mg of doxorubicin.
Study: NCT04622098

Intervention type: PROCEDURE
Intervention: Endoscopic ultrasound
Description: this is an endoscopic procedure for the assessment of the lesions, the following will be recorded:~1. the tumor location,~2. layer of origin,~3. maximal diameter,~4. regularity of extraluminal border,~5. echopattern,~6. presence of cystic spaces or echogenic foci.
Study: NCT01303315

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TANTALUS System
Description: An Active Implantable Pulse Generator Medical Device for the treatment of Obesity and Diabetes Type 2 and Obesity

Intervention type: DEVICE
Group type: OTHER
Intervention: TANTALUS System
Description: An Active Implantable Pulse Generator Medical Device for the treatment of Obesity and Diabetes Type 2 and Obesity

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TANTALUS System
Description: An Active Implantable Pulse Generator Medical Device for the treatment of Obesity and Diabetes Type 2 and Obesity
Study: NCT02626247

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin A +Long chain PUFA
Description: 3 capsules per day, two capsules at breakfast and one capsule at lunch, with a glass of water.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 capsules per day, two capsules at breakfast and one capsule at lunch, with a glass of water.
Study: NCT02808247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Pharmaceutical form: Soft gelatine capsule Pharmaceutical code: Nintedanib (BIBF1120) Source: Boehringer Ingelheim Pharma GmbH \& Co. KG Unit strength: 100 mg and 150 mg capsules Daily dose: 400 mg (200 mg twice daily p.o.) Route of administration: oral
Study: NCT02178358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2157299
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2157299
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sorafenib
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT03695328

Intervention type: BEHAVIORAL
Intervention: physical activity level

Intervention type: BEHAVIORAL
Intervention: Dietary Intake